What Is Epitalon? Research Background and Study Areas

This profile sets out what the Epitalon peptide is chemically, which study types make up its literature, and where that literature stops. It closes with how a lot is identified analytically, which connects to how a lot is analyzed before it is listed.

It belongs to the Journal’s compound profile series, alongside the MOTS-c research profile and the GHK-Cu research profile.

The article covers laboratory research only and contains no preparation or dosing information.

What the Epitalon peptide is chemically

Epitalon is a linear chain of four L-amino acids: alanine, glutamic acid, aspartic acid and glycine, in that order. PubChem lists its molecular formula as C14H22N4O9 and its molecular weight as 390.35, with Epithalon and Epithalone among its recorded synonyms.

The peptide came out of earlier work on Epithalamin. A 2025 review in the International Journal of Molecular Sciences describes Epitalon as synthesized on the basis of Epithalamin’s amino acid composition, and states that early research on the extract was led mainly by V. K. Khavinson and V. N. Anisimov. The sequence was designed first and looked for in tissue later. In a 2017 analytical study, Khavinson’s group reported detecting AEDG by mass spectrometry among the tetrapeptides of a pineal polypeptide complex.

Older papers report on either the extract or the peptide, and results for one cannot be read as results for the other without qualification.

What published research on Epitalon examines

Most published Epitalon work falls into three groups: cell culture studies of telomere biology, cell culture studies of gene expression, and animal studies. The 2025 review counts in vitro, in vivo and in silico work across roughly 25 years.

• Telomerase in fetal fibroblasts, in vitro. A 2003 cell culture study added Epitalon to telomerase-negative human fetal fibroblasts and reported expression of the telomerase catalytic subunit, telomerase enzymatic activity and telomere elongation.
• Passage number in fibroblast culture, in vitro. A 2004 follow-up used fetal lung fibroblasts that stopped dividing at passage 34 in control culture. Peptide-exposed cultures showed telomere lengths comparable to early passages and were still dividing at passage 44.
• Neurogenic markers in stem cells, in vitro and in silico. A 2020 study in human gingival mesenchymal stem cells measured Nestin, GAP43, beta III tubulin and Doublecortin at the protein and mRNA level and reported higher expression. Molecular modeling proposed binding sites on histones H1/3 and H1/6. The authors present the epigenetic mechanism as possible, not demonstrated.
• Biomarkers in mice, animal model. A 2003 study in female SHR mice followed 54 animals per group and measured body weight, estrous function, chromosome aberrations in bone marrow cells, spontaneous tumor incidence and survival. The authors reported no difference in body weight or mean survival, and differences in some secondary measures, including estrous function and chromosome aberration frequency.
• Telomere length in four human cell lines, in vitro. A 2025 study from Brunel University London measured telomere length by qPCR, hTERT expression, telomerase activity by TRAP assay, and ALT markers. In normal epithelial cells and fibroblasts the authors reported telomere lengthening with telomerase upregulation. In two breast cancer cell lines they reported lengthening associated with ALT activity.

None of these designs measures an outcome in a person. Each measures an enzyme, a marker, a passage count or an animal endpoint in one defined model.

How strong the evidence base for Epitalon is

It is narrow. Most of the record traces to one St. Petersburg research network centered on V. K. Khavinson and V. N. Anisimov. The St. Petersburg Institute of Bioregulation and Gerontology appears in the affiliations of the telomerase, pineal complex and stem cell papers above, and Khavinson is an author on every primary study in the previous section except the Brunel paper.

Independent replication is limited. The Brunel group, which shares no authors with the St. Petersburg papers, wrote that its results in normal cells agreed with the earlier telomerase findings. The same authors also wrote that very little quantitative data had been published comparing telomere length, hTERT expression, telomerase and ALT activity in exposed cells. Their own work was a 2D cell culture study, a limit they state themselves.

In practice, effect sizes in the early papers are single-laboratory estimates, and proposed mechanisms such as histone binding rest on modeling and one group’s assays. Reviews, including the 2025 overview, draw heavily on the same primary sources, so a count of reviews is not a count of independent studies.

What the Epitalon literature does not establish

The gaps are wider than the findings.

• Independent human data. The 2025 review describes a clinical trial run at the St. Petersburg Institute of Bioregulation and Gerontology. We did not find human data from an unaffiliated group.
• Organism-level effects from cell work. Telomerase activity or telomere length in a culture dish does not establish any effect in a whole animal or a person. The Brunel authors call for 3D culture and animal models as the next step.
• Generality of the mouse findings. The mouse work used one strain and one sex, came from one research network, and showed no difference in body weight or mean survival. It cannot be extended to other species.
• A settled mechanism. The 2025 review concludes that the mechanism of action remains unclear, and that physico-chemical and structural studies of the peptide are very limited.
• The meaning of the cancer cell result. The Brunel group described telomere lengthening through ALT in breast cancer cell lines as unexpected. Its significance has not been established.
• A federal safety finding. On its page of bulk drug substances that may present significant safety risks, FDA states that it has not identified safety-related information on epitalon for the proposed route and lacks sufficient information to know whether it would cause harm in humans. FDA also notes a potential for aggregation and peptide-related impurities.

Reading a certificate for an Epitalon lot

Research material is only as interpretable as its identity. For a short peptide, identity rests on mass and on sequence, and those are two different tests.

Mass spectrometry confirms that a molecule of the expected mass is present. On its own it cannot tell AEDG from a peptide with the same four residues in another order. In a 2015 analytical study, researchers used liquid chromatography with tandem mass spectrometry to identify Epitalon in two preparations labeled as containing it, and considered confusion with the isomer Glu-Ala-Asp-Gly. They separated the two by heating the sample, which converts an N-terminal glutamic acid to pyroglutamate and lowers its mass.

• Lot number on the certificate matches the lot number on the vial label
• Compound named as Epitalon with the full sequence Ala-Glu-Asp-Gly stated
• Molecular formula C14H22N4O9 and expected mass stated
• Identity confirmed by mass spectrometry with the observed mass reported
• Method able to distinguish sequence isomers, such as tandem mass spectrometry
• Chromatographic purity reported as a result for that lot
• Testing laboratory, test date and analyst sign-off recorded

A certificate describes one lot. It says nothing about another lot, and nothing about what the peptide does in any model. The research use only policy and the compliance overview set out the terms that apply to this material, and the frequently asked questions page covers documentation queries.

Goated Peptides publishes its lot records in the lot-matched certificate library. To check the points above against a real document, look up an Epitalon lot there and compare its lot number, sequence and mass spectrometry result with the vial label.

Frequently asked questions